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Abstract
Case presentation: This is an unusual case where a 49-year old female patient with known
schizophrenia, paranoid type and a history of early-stage breast cancer, which was treated more
than 6 years earlier, attempted suicide. Computed tomography and magnetic resonance imaging
after this incident revealed the presence of multiple brain metastases as the first symptomatic site
of recurrent cancer. Further staging lead to the diagnosis of lung, hilar and mediastinal lymph node
metastases and histology confirmed estrogen receptor-positive metastatic cancer. Treatment
consisted of whole-brain radiotherapy and letrozole. Twenty-one months later, the patient is in
continued partial remission.
Background
Breast cancer is one of the leading causes of brain metas-
tases [1]. These metastases usually develop late in the
course of the disease and often indicate rapid progression
and short overall survival time despite various local and
systemic treatment approaches [2]. Here the authors
present an unusual case of a patient with schizophrenia,
paranoid type (schizophrenia, PT) in whom a breast can-
cer relapse with multiple brain metastases was discovered
following a suicide attempt.
Case presentation
The patient (country of origin: Norway) is a caucasian
female diagnosed with schizophrenia, PT at the age of 15.
She had a history of alcohol and benzodiazepine abuse
and symptoms of depression over several years. Several
suicide attempts by intoxication were recorded before
1994. In April 1998, she had undergone mammography
without pathological findings. In autumn 1999 at the age
of 42 years, she had noted a small lump in her right breast,
which was diagnosed as breast cancer. In November 1999,
the patient was treated with modified mastectomy and
axillary dissection. Histology demonstrated infiltrating
ductal carcinoma grade I with associated intraductal carci-
noma in situ. The invasive component measured 10 mm.
The tumor was highly positive for estrogen receptor (ER)
expression (95%), but less than 10% positive for proges-
terone receptor (PR) expression. None of the axillary
lymph nodes was involved (in summary a T1 N0/7 M0 G1
ER+ PR+ breast cancer). Based on the treatment guidelines
at that time, the patient did not receive any type of adju-
vant treatment but follow-up examinations at regular
intervals.
In August 2006, the then 49 year-old patient attempted
suicide (she tried to hang herself) while on long-term
treatment with Levomepromazine and Olanzapine. After
having been examined by the emergency physician, she
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was admitted to the hospital's orthopaedic department,
where she reported irregular use of medication and
increased alcohol consumption over a couple of days. She
also reported about her recent nervousness and obsessive
thoughts about suicide, explaining that she wanted to
demonstrate her family that she was not interested in the
ongoing talks about her father's assets. Although her
father had passed away already one year earlier, there were
still some unresolved issues around this in the family. A
computed tomography scan (CT) of the brain at the day
of attempted suicide showed a single supratentorial mass,
while magnetic resonance imaging (MRI) revealed a total
of 3 supratentorial tumors (Figure 1). Neurologic exami-
nation was unremarkable. Further staging with CT dem-
onstrated the presence of enlarged mediastinal and left
hilar lymph nodes and a small intrapulmonary lesion on
the left side (Figure 2). A lymph node biopsy was taken to
exclude primary lung cancer in this patient with a history
of heavy smoking. Histology confirmed metastatic breast
cancer, ER positive, PR negative, HER2 score 3+. Blood
tests revealed pathologically elevated CA 15-3 (43 KU/
liter) and lactatdehydrogenase (LDH, 234 U/liter) as the
only abnormal measurements. No hypercalcemia, other
distant metastases, locoregional recurrence, or contralat-
eral breast cancer was detected. The patient was postmen-
opausal at that time (last menstruation in 2004).
With psychiatric support from her previous treatment
team and temporary use of Zuclopenthixol, suicidality
resolved and the patient tolerated the diagnostic proce-
dures and bad news resulting from these without impair-
ment of her condition. She was motivated to treatment
and provided informed consent. Treatment consisted of
whole-brain radiotherapy (WBRT, 10 fractions of 3 Gy) as
Baseline and follow-up brain imaging Figure 1
Baseline and follow-up brain imaging. Initial magnetic resonance imaging scans of the brain demonstrating a large frontal 
mass and multiple small lesions (left side and lower right, August 2006). Small residual frontal abnormality 11 months after 
whole-brain radiotherapy (upper right).Cases Journal 2008, 1:195 http://www.casesjournal.com/content/1/1/195
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inpatient on a regular oncology ward in September 2006
plus Letrozole 2.5 mg per day as continuous oral medica-
tion. No unplanned interruption of treatment was neces-
sary. In February 2007, brain MRI showed a partial
remission and the lung lesions were in minor response.
CA 15-3 and LDH levels were lower, 35 KU/liter and 152
U/liter, respectively. In August 2007, these figures were 25
KU/liter and 150 U/liter, respectively. Thus, these markers
were not longer pathologically elevated. MRI showed con-
tinuous partial remission (Figure 1). The last clinical fol-
low-up examination was performed in May 2008. No
potential signs of disease progression were detectable, CA
15-3 was 17 KU/liter, the lung lesion was markedly
reduced in size on CT (Figure 2), and treatment with
Letrozole continues. The now 51 year-old patient has a
Karnofsky performance status (KPS) of 70% resulting
from her known psychiatric disorder. She has no obvious
late toxicity from WBRT (no detailed neurocognitive test-
ing has been performed).
Discussion
Patients with schizophrenia, PT have a risk of suicide that
is much higher than that of the general population, e.g.,
16 times higher in the study by Limosin et al. [3] and 13
times higher in the study by Osborn et al. [4]. In forensic
autopsy, such incidents are rarely related to undiagnosed
brain tumors, however Shiferaw et al. described a case of
frontal glioblastoma diagnosed post mortem [5]. Other
authors suggested that pituitary microadenoma and tem-
poral lobe tumors might also be associated with suicide
risk [6,7]. Suicide after breast cancer is also more common
than suicide in the general population. In the large study
by Schairer et al., the risk was elevated throughout follow-
up and dependent on stage of disease [8]. The standard-
ized mortality ratio was 1.37 and the excess absolute risk
4.1 per 100,000 person years. Cancer patients might also
present with agitation, disorientation and hallucinations
[9], major depression [10], and cognitive deficits [11] in
the course of the disease. It was estimated that structural
brain lesions were the sole cause of altered mental status
in 15% of patients [9]. Whether the attempted suicide in
the patient described here was caused by the presence of
multiple brain metastases is hard to determine, but it
appears possible. No other neurologic symptoms or signs
of recurrent breast cancer were present at this time. In fact,
only imaging after the attempted suicide disclosed breast
cancer relapse incl. spread to the lung, hilar and mediasti-
nal lymph nodes. Given the low-risk features at initial
diagnosis, the aggressive pattern of recurrence is surpris-
ing. However, no evaluation of HER2 status was per-
formed in 1999 when the initial diagnosis was made.
Treatment with WBRT and Letrozole was chosen after
careful consideration of the patient's ability to tolerate the
potential side effects of systemic treatment, her psychiatric
comorbidity, the high ER expression of the metastases and
the survival statistics of patients with multiple brain
metastases. It was felt that more aggressive approaches
would compromise the patient's compliance. WBRT plays
an important role in the palliative treatment of multiple
brain metastases. However, the median survival is limited
to 4–6 months [2,12-14]. Performance status is the most
important prognostic factor for survival [2,12,13]. Lym-
phopenia, which was not present in our patient, might
play an additional role [12]. Regarding the 3 recursive par-
titioning analysis classes [15], which might be used to esti-
mate survival, our patient belonged to class 2 because
extracranial metastases were present. Median survival in
class 2 breast cancer patients was reported to be 6.5
months in the study by Johansen et al. [14]. Thus, the out-
come was unexpectedly favourable in the patient dis-
cussed here. Recently, it has been repeatedly reported that
administration of systemic therapy after WBRT improves
survival [13,16]. Also in the patient presented here, the
extracranial metastases responded to endocrine therapy,
Baseline and follow-up lung imaging Figure 2
Baseline and follow-up lung imaging. Computed tomog-
raphy scans of the chest at diagnosis of metastatic breast can-
cer demonstrate a left hilar mass of 2.44 cm diameter (upper 
image, August 2006). In November 2007, a continued partial 
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which might contribute to prolongation of survival. Treat-
ment tolerance and patient's compliance were excellent.
Several salvage options incl. radiosurgery for progressive
brain metastases, second-line endocrine treatment, chem-
otherapy, trastuzumab and lapatinib can be administered
if disease progression is encountered during further fol-
low-up [17]. With the excellent response to endocrine
therapy, second line endocrine therapy should be the first
choice.
Conclusion
This case illustrates that brain metastases in patients with
both cancer and schizophrenia, PT might lead to unex-
pected serious disease complications.
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